Is Current Biology a Good Journal? A Practical Fit Verdict
A practical Current Biology fit verdict for authors deciding whether their paper is broad and concise enough for the journal.
Research Scientist, Neuroscience & Cell Biology
Author context
Works across neuroscience and cell biology, with direct expertise in preparing manuscripts for PNAS, Nature Neuroscience, Neuron, eLife, and Nature Communications.
Journal fit
See whether this paper looks realistic for Current Biology.
Run the Free Readiness Scan with Current Biology as your target journal and see whether this paper looks like a realistic submission.
Current Biology at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 9.2 puts Current Biology in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~35% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: Current Biology takes ~30-45 days. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to read Current Biology as a target
This page should help you decide whether Current Biology belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | Current Biology covers the full spectrum of biological sciences, but that doesn't mean anything goes. |
Editors prioritize | The 'huh, that's weird' factor |
Think twice if | Burying the lead in specialist jargon |
Typical article types | Article, Report, Correspondence |
Quick answer
Yes, Current Biology is a good journal. It is a respected Cell Press venue for broad-interest biology and is especially strong for papers that make one sharp point cleanly. But the real question is whether the manuscript becomes stronger when compressed rather than weaker. If it needs a long specialist buildup, a heavy methods appendix, or multiple layers of field-specific framing to feel important, Current Biology is usually the wrong home even when the science itself is good.
Current Biology at a glance
Metric | Current signal |
|---|---|
2024 impact factor | 7.5 |
Publisher | Cell Press |
Best fit | Concise, broadly interesting biology |
Common format logic | Shorter, cleaner, high-signal stories |
Editorial risk | Fast rejection for papers that feel too niche |
How Current Biology compares to nearby options
Journal | Best use case | When it is stronger than Current Biology |
|---|---|---|
Current Biology | Broad-interest biology with one sharp message | When the story is concise and cross-field appealing |
Cell | Larger-scale, more transformative biology | When the paper is simply operating at a higher general-impact level |
Cell Reports | Data-richer cell and molecular biology | When the paper needs more space and mechanistic detail |
eLife | Longer-form rigorous biology with different editorial culture | When the paper benefits from fuller exposition rather than compression |
Specialty journals | Narrower disciplinary readership | When the result mainly matters within one field |
Current Biology is not a consolation prize for Cell. It is best for a different shape of paper.
What the journal is actually selecting for
Current Biology openly describes itself as a general biology journal whose aim is to foster communication across fields of biology. That means the journal is looking for papers that non-specialists can read without feeling locked out.
In practice, editors are usually asking:
- is the central result intelligible to biologists outside the exact specialty
- does the manuscript have one clean takeaway
- can the paper survive a concise format without collapsing
- is the broad-interest claim visible in the paper itself, not just in the cover letter
That last point matters. Many authors describe their work as broad. Far fewer actually write it that way.
Why Current Biology is strong
Current Biology is strong because it gives broad but not mega-scale biology a real editorial home. Not every important paper should be a sprawling mechanistic epic. Some papers are genuinely best as concise discoveries that shift how biologists think.
That is the niche Current Biology serves.
It also benefits from the Cell Press system: professional editors, recognizable brand, and a readership accustomed to curated high-signal biology. For the right paper, that is a very strong combination.
What I would tell an author
If an author asked me whether Current Biology is right for their study, I would ask:
Can a biologist from another field understand why this matters in the first paragraph?
If the answer is yes, the journal may be a strong fit.
If the answer is no, and the paper only becomes impressive after a dense methods or literature briefing, then the honest home is often a specialty journal or a longer-format venue.
That is not a downgrade. It is recognizing what the paper actually is.
What we see before submission
In our pre-submission review work, Current Biology misses are usually very recognizable.
The paper is interesting but too specialist to travel. The result matters, but only readers already deep in the subfield can see why.
The story needs too much scaffolding. Authors often try to fit a paper that really needs a longer journal into a Current Biology shape, and the compression exposes structural weakness.
The broad-interest claim lives in the pitch, not the manuscript. The cover letter says the work matters across biology, but the abstract and first figures do not support that claim.
That is where a pre-submission broad-interest check helps. It is a fast way to test whether the manuscript actually reads like Current Biology instead of merely aspiring to it.
Submit If / Think Twice If
Submit if:
- the manuscript makes one clear biological point with broad interest
- the paper becomes stronger when written tightly
- the result is easy to explain to non-specialists
- the finding is surprising, elegant, or conceptually clarifying
- the manuscript does not depend on huge amounts of supplemental scaffolding
Think twice if:
- the paper is mainly for one specialty audience
- the story requires extensive depth to become convincing
- the manuscript needs more space than the journal naturally rewards
- the result is incremental outside a narrow field
- a specialty journal would describe the contribution more honestly
Journal fit
See whether this paper looks realistic for Current Biology.
Run the scan with Current Biology as the target. Get a manuscript-specific fit signal before you commit.
A useful external signal from authors
SciRev reports are helpful here too. Current Biology author reviews show very fast immediate rejections, sometimes in just a few days, and positive reports often emphasize responsive editors plus constructive reviews when the paper clearly fits.
That matches the journal's real operating style: the editorial screen is fast because broad-interest fit is visible early.
This is a journal for papers that get cleaner when simplified
One of the clearest ways to decide on Current Biology is to ask what happens when you simplify the manuscript.
If simplifying makes the story look sharper, more elegant, and easier to care about, that is a good sign.
If simplifying makes the story look thin, overly local, or under-supported, that is a warning that the journal shape may be wrong.
That is a more useful test than prestige talk.
Bottom line
Current Biology is a good journal when the paper has one broad, crisp biological message and fits a concise format honestly.
The practical verdict is:
- yes, when the manuscript is sharp, cross-field readable, and stronger when compressed
- no, when the paper is too specialist, too scaffold-heavy, or too dependent on long-form explanation
That is the fit verdict authors actually need.
Frequently asked questions
Yes. Current Biology is a strong Cell Press journal for broadly interesting biology, especially papers that can make one sharp point quickly to readers outside the immediate specialty.
Current Biology fits concise papers with one clear biological message and broad interest across biology. It is weaker for specialist-heavy manuscripts that only make sense after a long technical buildup.
No. It is a different editorial product. Cell wants more transformative depth and scale. Current Biology is built for concise, high-interest biology that travels well across fields.
Common weak fits are niche papers that require too much specialist context, stories that need too much supplementary scaffolding to land, and manuscripts whose broad-interest claim exists only in the cover letter.
Sources
- 1. Current Biology journal homepage, Cell Press.
- 2. Current Biology authors page, Cell Press.
- 3. Current Biology overview in Cell Press event materials, Cell Press.
- 4. Current Biology on SciRev, SciRev.
- 5. Current Biology reviews on SciRev, SciRev.
Final step
See whether this paper fits Current Biology.
Run the Free Readiness Scan with Current Biology as your target journal and get a manuscript-specific fit signal before you commit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- Current Biology Submission Guide
- How to avoid desk rejection at Current Biology
- Current Biology Review Time: What Authors Can Actually Expect
- Current Biology Impact Factor 2026: 7.5 - Cell Press's Broad Biology Journal
- Current Biology Cover Letter: What Editors Actually Need to See
- Current Biology Formatting Requirements: The Submission Package Guide
Compare alternatives
Supporting reads
Conversion step
See whether this paper fits Current Biology.
Anthropic Privacy Partner. Zero-retention manuscript processing.